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Managing expense and expectation in a treatment revolution: Problematizing 
prioritisation through an exploration of hepatitis C treatment ‘benefit’.   
 
ABSTRACT 
Background: Direct-acting antivirals (DAAs) have transformed the hepatitis C (HCV) treatment 
landscape. These highly effective drugs are, however, not available to all. In a context of DAA 
rationing, clinicians are advised to “manage patient expectations” about the benefits of a HCV cure. 
This directive particularly pertains to people with minimal liver damage and those who have ceased 
injecting: populations negated in contemporary prioritisation debates. 
Methods: This paper engages with the assumptions underpinning HCV treatment prioritisation 
discourses to explore the concept of treatment ‘benefit’ from patient perspectives. Data are from a 
qualitative longitudinal study exploring treatment transitions and decision-making from 2012-2015. 
Participants comprised 28 people living with HCV, ten treatment providers and eight stakeholders, 
based in London, United Kingdom (UK). One hundred hours of clinic observations were conducted at 
two HCV treatment hospitals. Thematic analyses pertaining to treatment expectation and outcome 
inform this paper. 
Findings:  Twenty-two participants commenced treatment.  The majority who were unable to access 
DAAs chose to commence interferon-based treatment immediately rather than wait. Participants 
accounted for treatment urgency in relation to three interrelated narratives of hope and 
expectation. HCV treatment promised: social reconnection; social redemption and a return to 
‘normality’. For many with successful treatment outcomes, these benefits appeared to be realised.  
Conclusion: The DAA era heralds a discursive shift: from ‘managing [interferon] risk and difficulty’ to 
‘managing [DAA] expense and expectation’. Calls to ‘manage patient expectations’ about the 
benefits of HCV cure are predicated on clinical benefits only, negating the social impacts of living 
with HCV. The public health priorities commonly articulated in treatment prioritisation debates are 
not consistent with those of people managing illness in their daily lives. During this ‘treatment 
revolution’ there is a need to be cognisant of the multiple publics living with the virus and the 
treatment needs of those who do not fit population-health scenarios. 
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